Specialty Pharma Journal Specialty, Precision & Technology
NEW YORK & SAN FRANCISCO–(BUSINESS WIRE)–The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company (NYSE: BMY) and the Cancer Research Institute (CRI) today announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks. Bristol-Myers Squibb will work closely …
Tag Archives: precision medicine
March, 2017
-
27 March
New Era in Precision Medicine for Pancreatic Cancer
The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK. The investment will support the PRECISION Panc* project which aims to develop …
-
17 March
Three Harvard Experts Explain how Economics Can Shape Precision Medicines
Author affiliations: Harvard Business School, Harvard Medical School, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Kennedy School Many public and private efforts focus on research in precision medicine, the process by which genomic information and other characteristics of a patient’s disease are used to predict which treatments will be most effective. …
-
1 March
Bristol-Myers Squibb Expands Focus on Precision Medicine with Investment and Planned Collaboration with GRAIL on Cancer Screening
NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) announced today its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is to detect cancer early when it potentially can be cured. By combining the power of high intensity cancer DNA sequencing, leading edge …
February, 2017
-
10 February
Research Uncovers Bacteria Linking Crohn’s Disease to Arthritis
Patients with Crohn’s disease, a type of inflammatory bowel disease (IBD) that causes abdominal pain and diarrhea, can also experience joint pain. In Crohn’s disease, which affects about 800,000 Americans, the immune system can attack not only the bowels, but the musculoskeletal system as well, leading to spondyloarthritis, a painful …
January, 2017
-
25 January
Researchers Discover Potential New Target for Treating Glioblastoma
DALLAS – January 24, 2017 – Scientists have found a way to inhibit the growth of glioblastoma, a type of brain cancer with low survival rates, by targeting a protein that drives growth of brain tumors, according to research from the Peter O’Donnell Jr. Brain Institute and Harold C. Simmons …
-
25 January
PMC Analysis: Personalized Medicines Top 20 Percent of FDA Approvals For Third Straight Year
WASHINGTON (January 24, 2017) — A new report from the Personalized Medicine Coalition (PMC) shows that in 2016, for the third year in a row, personalized medicines accounted for more than 20 percent of the new molecular entities (NMEs) approved by the U.S. Food and Drug Administration (FDA). PMC President …
-
6 January
AACR Project GENIE Releases Large Cancer Genomic Data Set Which Will Aid in Development of Precision Medicine
PHILADELPHIA — The American Association for Cancer Research (AACR) today announced the first public release of cancer genomic data aggregated through its initiative known as AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE). The data set includes nearly 19,000 de-identified genomic records collected from patients who were treated at eight …
December, 2016
-
14 December
Subtype of Triple Negative Breast Cancer Responds Better to Chemotherapy
Researchers at Yale Cancer Center have identified a new subtype of triple negative breast cancer that shows significantly improved response to chemotherapy. Patients with the newly defined subtype — BRCA-deficient triple negative breast cancer — had significantly higher survival rates with chemotherapy. The study was published on Dec. 13 in …
-
9 December
Personalized Cancer Vaccine is Associated with Promising outcomes for Patients with AML
A personalized cancer vaccine markedly improved outcomes for patients suffering from acute myeloid leukemia (AML), a potentially lethal blood cancer, in a clinical trial led by investigators at Beth Israel Deaconess Medical Center (BIDMC). The product of a long-term collaboration among investigators at the Cancer Center at BIDMC and Dana-Farber …